NVO
Novo Nordisk A/S
NVO has the edge over SRPT overall, supported by lower modeled downside and stronger fundamentals.
SRPT
Sarepta Therapeutics, Inc.
SRPT offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SRPT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Healthy | |
| Weak |
SRPT's cash flow is currently healthy, and its profitability is stable, but its revenue and balance sheet are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SRPT PE Valuation
SRPT has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
NVO has the edge over SRPT on the outlook, with more favorable earnings and revenue expectations.
SRPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect SRPT's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SRPT on earnings quality, reporting a profit while its opponent remains loss making.
SRPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.37 | +$1.58 |
| Q2 2026 | -$2.90 | -$2.09 |
| Q1 2026 | -$0.96 | +$1.67 |
| Q4 2025 | -$8.44 | -461% |
| Q3 2025 | -$2.95 | -288% |
| Q2 2025 | -$0.81 | -205% |
| Q1 2025 | -$2.63 | -712% |
| Q4 2024 | $2.34 | +$8.14 |
SRPT is still losing money, but far less than before: $1.37 per share over the past year, against $12.69 at its worst in early 2023.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over SRPT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SRPT on profitability, with a higher operating margin.
SRPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $381.4M | -4.5% |
| Q2 2026 | $401.3M | -34% |
| Q1 2026 | $730.8M | -1.9% |
| Q4 2025 | $442.9M | -33% |
| Q3 2025 | $399.4M | -15% |
| Q2 2025 | $611.1M | +68% |
| Q1 2025 | $744.9M | +80% |
| Q4 2024 | $658.4M | +66% |
SRPT's revenue has slid since its 2025 peak: $381M last quarter, down 4.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.4% | +24 points |
| Q2 2026 | 3.3% | -16 points |
| Q1 2026 | 49% | +89 points |
| Q4 2025 | -93% | -118 points |
| Q3 2025 | -26% | -31 points |
| Q2 2025 | 19% | +19 points |
| Q1 2025 | -40% | -49 points |
| Q4 2024 | 25% | +18 points |
SRPT's operating margin was −2.4% last quarter, up 24 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
SRPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $57M | +$94.6M |
| Q2 2026 | $196.5M | -14% |
| Q1 2026 | -$204.8M | +$422.3M |
| Q4 2025 | $127.6M | +136% |
| Q3 2025 | -$37.5M | +$70.4M |
| Q2 2025 | $229.5M | +$243.8M |
| Q1 2025 | -$627.1M | -$352.6M |
| Q4 2024 | $54M | +$127.7M |
SRPT has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SRPT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SRPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +499K shares |
| 1 year | +5.7% | +5.7M shares |
| 3 years | +19% | +17M shares |
| 5 years | +36% | +28M shares |
SRPT has 106M diluted shares, up 5.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over SRPT on leverage, with a lower net debt burden relative to earnings.
SRPT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 89.5x | High |
| Q2 2025 | -12.7x | Net Cash |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | 8.6x | High |
| Q2 2024 | 10.8x | High |
SRPT's net debt is more than 20 years of its operating earnings (EBITDA), up from 11 years a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SRPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.3 | Neutral |
| Stochastic | 26.2 | Neutral |
SRPT's weekly RSI is 42 (neutral) and its Stochastic is 26 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SRPT PE vs Healthcare Sector
| Metric | SRPT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SRPT has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over SRPT on trend strength, trading above more of its moving averages.
SRPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.7 | 9.3% below |
| 20 week MA | $18.2 | 12% below |
| 50 week MA | $18.9 | 15% below |
| 100 week MA | $35.3 | 55% below |
| 200 week MA | $78.9 | 80% below |
SRPT is in a downtrend: it's below all five of its weekly moving averages, and 80% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over SRPT on returns for 2026, with the stronger performance.
SRPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $129.8 | $175.0 | +35% |
| 2021 | $175.0 | $91.6 | -48% |
| 2022 | $91.6 | $130.0 | +42% |
| 2023 | $130.0 | $96.4 | -26% |
| 2024 | $96.4 | $121.5 | +26% |
| 2025 | $121.5 | $22.1 | -82% |
| 2026 YTD | $22.1 | $16.0 | -28% |
SRPT has finished lower in three of the last six years. It's down 28% so far in 2026.